Dr. Scott Lippman
Dr. Scott Lippman is the director of Moores Cancer Center. Find out more about him.
Making an Impact on Cancer Together
The UC San Diego Moores Cancer Center employs a multi-disciplinary team approach to translate our research faculty’s basic scientific discoveries into new treatments for cancer patients in the clinic. We are home to 413 scientists and physicians from 17 university departments. Our faculty includes a Nobel laureate and 14 members of the National Academy of Sciences. The hallmark of Moores Cancer Center research has been taking discoveries to the clinic. Our most recent example: [99mTc]Tilmanocept, a new imaging dye that more effectively identifies and maps cancer cells, received FDA approval in March. It was fully developed here from lab discovery through registration clinical testing. (See press release for more information.)
Why do we strive for this kind of excellence? Because of people like Kay Mueller, who for her 50th birthday, decided to undergo a complete physical exam, including a colonoscopy. The test revealed Stage 3 colorectal cancer. By acting, Kay’s cancer was discovered before it was too late. Kay is now a major proponent of colonoscopies, an exam she credits for saving her life. (Watch a video that follows Kay through her treatment and surgery.)
Our strength in transforming cancer care and providing exceptional care to cancer patients is among the reasons that we were elected in March as the first and only San Diego-based National Comprehensive Cancer Network® Member Institution, a prominent coalition of the leading cancer centers. As a Member Institution, Moores Cancer Center will be part of a national network that develops the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) used as the standard for clinical policy in oncology, incorporating expert medical judgment and recommendations of multidisciplinary panels from NCCN Member Institutions.
The fight against cancer requires a team effort, one that includes extraordinary physicians and scientists like those at Moores Cancer Center. We can strive to advance personalized cancer therapy to impact the outcomes of cancer care and to influence the direction of the cancer field if we work with other like-minded organizations such as the National Comprehensive Cancer Network and the Worldwide Innovative Network (WIN) Consortium.
We were invited to join the WIN Consortium in personalized cancer medicine earlier this year. Collaborating with WIN enables us to propose and participate in ground-breaking, global clinical trials with leading organizations advancing personalized cancer medicine and the benefits of genome-driven discoveries to patients. WIN was founded in 2010 by the University of Texas MD Anderson Cancer Center and the Institut Gustave Roussy in France. It is a global network of 29 universities, patient advocacy groups and companies representing the pharmaceutical, biotechnological and healthcare IT industries, all working together to accelerate the pace of translational cancer treatments at lower costs. Razelle Kurzrock, MD, Moores Cancer Center senior deputy director for clinical science, serves as a co-principal investigator for the WINther trial. This trial represents a cutting-edge global initiative to utilize advanced molecular profiling, including next generation DNA sequencing and transcriptome analysis, in order to optimize therapy for patients with advanced cancer.
We look forward to working with fellow premier institutions to improve cancer care outcomes of cancer care and to beneficially influence the direction of cancer research.
This update was featured in Moores Cancer Center's April 2013 email newsletter. If you don't receive it, you can subscribe here.
Read past messages: